Twenty years on, risk management in the pharmaceutical world continues to be challenging. Ensure that risk assessments are systematic, structured, and based on scientific knowledge. A large part of the ICH Q9(R1) revision was written to address continued struggles with subjectivity, formality, and decision-making. And quite frankly, it’s clear to me that we, as an … Continue reading Assessing the Quality of Our Risk Management Activities